医学
溶栓
血管成形术
心脏病学
特奈特普酶
心肌梗塞
血栓
无回流现象
内科学
导管室
重症监护医学
蒂米
纤溶
心力衰竭
心室颤动
急性冠脉综合征
纤溶剂
冠状动脉血栓形成
经皮冠状动脉介入治疗
介入心脏病学
梗塞
冠状动脉疾病
血流
微循环
冠状动脉血流储备
冠状动脉闭塞
冠状动脉粥样硬化
心导管术
动脉
作者
Youssef Fihri,Driss Britel,Fatima Ezahra Elktaibi,Aatif Benyass,Zouhair Lakhal
出处
期刊:Cureus
[Cureus, Inc.]
日期:2026-03-27
卷期号:18 (3): e105951-e105951
标识
DOI:10.7759/cureus.105951
摘要
No-reflow is a recurring phenomenon during coronary angioplasty that consists of the failure to reestablish blood flow after clearing an occluded coronary artery. Several treatments have been proposed for the management of no-reflow, including intracoronary thrombolysis, which has emerged in recent years as one of the means of managing this phenomenon. We report the case of a 68-year-old female patient with a high cardiovascular risk, admitted for the management of non-ST-elevation acute coronary syndrome, who presented a no-reflow phenomenon after angioplasty of the right coronary artery. After the failure of the various means available to reopen the artery, a 30 mg dose of tenecteplase was administered intracoronary with restoration of Thrombolysis in Myocardial Infarction III flow in the angiographic control and good clinical and rhythmic evolution. Fibrinolytic agents remain an effective means in the treatment of acute coronary syndromes with ST-segment elevation. Its use in intracoronary therapy has demonstrated its benefit in restoring flow and improving microcirculation while maintaining a satisfactory safety profile. The use of these agents in the treatment of no-reflow remains an alternative to the usual treatment, such as adenosine and verapamil, and mechanical means, such as thrombo-aspiration, allowing dissolution of the thrombus and reestablishment of the flow. The management of no-reflow phenomena remains difficult, given the varied pathophysiology of this phenomenon and the therapeutic arsenal available for its management. However, intracoronary thrombolysis for the management of no-reflow remains an attractive and interesting alternative with results that remain acceptable, but which need to be approved by studies on larger samples with more details on the dose and the administration methodology.
科研通智能强力驱动
Strongly Powered by AbleSci AI